Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Pulmonary/Respiratory Diseases | Family Medicine
Disease Category: Lung Cancer
Location: United States, ND

Clinical Trial Details

Overview

Research Study Summary

Advanced Stage Non-small Cell Lung Cancer

Purpose

Study to evaluate the long-term safety and efficacy of Darbepoetin Alfa in anemic subjects with Advanced Stage Non-small Cell Lung Cancer receiving multi-cycle chemotherapy.

Patient Inclusion Criteria:

  • Subjects with metastatic (stage IV) Non-small Cell Lung cancer, receiving or about receive first line cyclic chemotherapy, life expectancy >6 months, 18 years and older

Patient Exclusion Criteria:

  • Subjects with a history of brain metastasis, known primary benign or malignant hematologic disorder which can cause anemia, history of or current, active cancer (other than non-small lung), uncontrolled angina, uncontrolled heart failure or uncontrolled chronic cardiac arrhythmia, subject with history of a seizure disorder.

To Learn more
Phase

3

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131

View Map

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 163093

Date Last Changed: July 24, 2013


DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.